Deciphering pro-lymphangiogenic programs during mammary involution and postpartum breast cancer

Frontiers in Oncology

Volumn 6, Issue NOV, 2016, Pages

  Borges, Virginia F ^a,b   Elder, Alan M ^a,b   Lyons, Traci R ^a,b  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Lymphangiogenesis; Lymphatic metastasis; Macrophages; Postpartum

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

BLOOD VESSEL PARAMETERS; CANCER RISK; FEMALE; HUMAN; LYMPH NODE METASTASIS; LYMPHANGIOGENESIS; LYMPHATIC VESSEL DENSITY; METASTASIS; METASTATIC BREAST CANCER; NONHUMAN; PREGNANT WOMAN; PUERPERIUM; SHORT SURVEY; TUMOR ASSOCIATED LEUKOCYTE; TUMOR VASCULARIZATION;

EID: 85006488610     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2016.00227     Document Type: Short Survey

References (134)

1. Lyons TR, O'Brien J, Borges VF, Conklin MW, Keely PJ, Eliceiri KW, et al. Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2. Nat Med (2011) 17:1109-15. doi:10.1038/nm.2416
2. Neill T, Zoeller J. Matrix biology highlights. Matrix Biol (2014) 40:1-4. doi:10.1016/j.matbio.2014.11.002
3. Borges VF, Schedin PJ. Pregnancy-associated breast cancer: an entity needing refinement of the definition. Cancer (2012) 118:3226-8. doi:10.1002/cncr.26643
4. Lyons TR, Schedin PJ, Borges VF. Pregnancy and breast cancer: when they collide. J Mammary Gland Biol Neoplasia (2009) 14:87-98. doi:10.1007/s10911-009-9119-7
5. Callihan EB, Gao D, Jindal S, Lyons TR, Manthey E, Edgerton S, et al. Postpartum diagnosis demonstrates a high risk for metastasis and merits an expanded definition of pregnancy-associated breast cancer. Breast Cancer Res Treat (2013) 138:549-59. doi:10.1007/s10549-013-2437-x
6. Liu Q, Wuu J, Lambe M, Hsieh SF, Ekbom A, Hsieh CC. Transient increase in breast cancer risk after giving birth: postpartum period with the highest risk (Sweden). Cancer Causes Control (2002) 13:299-305. doi:10.1023/A:1015287208222
7. Borges VF, Goddard E, Partridge AH, Schedin P. Abstract P6-08-08: postpartum breast cancer demonstrates increased liver and brain metastasis with a proposed role for postpartum involution. Cancer Res (2015). doi:10.1158/1538-7445.SABCS14-P6-08-08
8. Fornetti J, Martinson HA, Betts CB, Lyons TR, Jindal S, Guo Q, et al. Mammary gland involution as an immunotherapeutic target for postpartum breast cancer. J Mammary Gland Biol Neoplasia (2014) 19:213-28. doi:10.1007/s10911-014-9322-z
9. Asztalos S, Gann PH, Hayes MK, Nonn L, Beam CA, Dai Y, et al. Gene expression patterns in the human breast after pregnancy. Cancer Prev Res (Phila) (2010) 3:301-11. doi:10.1158/1940-6207.CAPR-09-0069
10. Atabai K, Sheppard D, Werb Z. Roles of the innate immune system in mammary gland remodeling during involution. J Mammary Gland Biol Neoplasia (2007) 12:37-45. doi:10.1007/s10911-007-9036-6
11. Clarkson RW, Heeley JL, Chapman R, Aillet F, Hay RT, Wyllie A, et al. NF-kappaB inhibits apoptosis in murine mammary epithelia. J Biol Chem (2000) 275:12737-42. doi:10.1074/jbc.275.17.12737
12. Clarkson RW, Wayland MT, Lee J, Freeman T, Watson CJ. Gene expression profiling of mammary gland development reveals putative roles for death receptors and immune mediators in post-lactational regression. Breast Cancer Res (2004) 6:R92-109. doi:10.1186/bcr754
13. Alexander CM, Selvarajan S, Mudgett J, Werb Z. Stromelysin-1 regulates adipogenesis during mammary gland involution. J Cell Biol (2001) 152:693-703. doi:10.1083/jcb.152.4.693
14. Djonov V, Andres AC, Ziemiecki A. Vascular remodelling during the normal and malignant life cycle of the mammary gland. Microsc Res Tech (2001) 52:182-9. doi:10.1002/1097-0029(20010115)52:2<182::AID-JEMT1004>3.0.CO;2-M
15. Green KA, Lund LR. ECM degrading proteases and tissue remodelling in the mammary gland. Bioessays (2005) 27:894-903. doi:10.1002/bies.20281
16. Hughes K, Wickenden JA, Allen JE, Watson CJ. Conditional deletion of Stat3 in mammary epithelium impairs the acute phase response and modulates immune cell numbers during post-lactational regression. J Pathol (2012) 227:106-17. doi:10.1002/path.3961
17. Monks J, Geske FJ, Lehman L, Fadok VA. Do inflammatory cells participate in mammary gland involution? J Mammary Gland Biol Neoplasia (2002) 7:163-76. doi:10.1023/A:1020351919634
18. Nickerson SC. Immunological aspects of mammary involution. J Dairy Sci (1989) 72:1665-78. doi:10.3168/jds.S0022-0302(89)79278-X
19. O'Brien J, Lyons T, Monks J, Lucia MS, Wilson RS, Hines L, et al. Alternatively activated macrophages and collagen remodeling characterize the postpartum involuting mammary gland across species. Am J Pathol (2010) 176:1241-55. doi:10.2353/ajpath.2010.090735
20. O'Brien J, Schedin P. Macrophages in breast cancer: do involution macrophages account for the poor prognosis of pregnancy-associated breast cancer? J Mammary Gland Biol Neoplasia (2009) 14:145-57. doi:10.1007/s10911-009-9118-8
21. Pensa S, Watson CJ, Poli V. Stat3 and the inflammation/acute phase response in involution and breast cancer. J Mammary Gland Biol Neoplasia (2009) 14:121-9. doi:10.1007/s10911-009-9124-x
22. Ramirez RA, Lee A, Schedin P, Russell JS, Masso-Welch PA. Alterations in mast cell frequency and relationship to angiogenesis in the rat mammary gland during windows of physiologic tissue remodeling. Dev Dyn (2012) 241:890-900. doi:10.1002/dvdy.23778
23. Schedin P, Mitrenga T, McDaniel S, Kaeck M. Mammary ECM composition and function are altered by reproductive state. Mol Carcinog (2004) 41:207-20. doi:10.1002/mc.20058
24. Schedin P, Strange R, Mitrenga T, Wolfe P, Kaeck M. Fibronectin fragments induce MMP activity in mouse mammary epithelial cells: evidence for a role in mammary tissue remodeling. J Cell Sci (2000) 113(Pt 5):795-806.
25. Stein T, Morris JS, Davies CR, Weber-Hall SJ, Duffy MA, Heath VJ, et al. Involution of the mouse mammary gland is associated with an immune cascade and an acute-phase response, involving LBP, CD14 and STAT3. Breast Cancer Res (2004) 6:R75-91. doi:10.1186/bcr894
26. Stein T, Salomonis N, Gusterson BA. Mammary gland involution as a multi-step process. J Mammary Gland Biol Neoplasia (2007) 12:25-35. doi:10.1007/s10911-007-9035-7
27. Stein T, Salomonis N, Nuyten DS, van de Vijver MJ, Gusterson BA. A mouse mammary gland involution mRNA signature identifies biological pathways potentially associated with breast cancer metastasis. J Mammary Gland Biol Neoplasia (2009) 14:99-116. doi:10.1007/s10911-009-9120-1
28. Strange R, Li F, Saurer S, Burkhardt A, Friis RR. Apoptotic cell death and tissue remodelling during mouse mammary gland involution. Development (1992) 115:49-58.
29. Talhouk RS, Bissell MJ, Werb Z. Coordinated expression of extracellular matrix-degrading proteinases and their inhibitors regulates mammary epithelial function during involution. J Cell Biol (1992) 118:1271-82. doi:10.1083/jcb.118.5.1271
30. Watson CJ. Post-lactational mammary gland regression: molecular basis and implications for breast cancer. Expert Rev Mol Med (2006) 8:1-15. doi:10.1017/S1462399406000196
31. Watson CJ. Involution: apoptosis and tissue remodelling that convert the mammary gland from milk factory to a quiescent organ. Breast Cancer Res (2006) 8:203. doi:10.1186/bcr1401
32. Watson CJ. Immune cell regulators in mouse mammary development and involution. J Anim Sci (2009) 87:35-42. doi:10.2527/jas.2008-1333
33. Werb Z, Ashkenas J, MacAuley A, Wiesen JF. Extracellular matrix remodeling as a regulator of stromal-epithelial interactions during mammary gland development, involution and carcinogenesis. Braz J Med Biol Res (1996) 29:1087-97.
34. Zhao L, Melenhorst JJ, Hennighausen L. Loss of interleukin 6 results in delayed mammary gland involution: a possible role for mitogen-activated protein kinase and not signal transducer and activator of transcription 3. Mol Endocrinol (2002) 16:2902-12. doi:10.1210/me.2001-0330
35. Kreuzaler PA, Staniszewska AD, Li W, Omidvar N, Kedjouar B, Turkson J, et al. Stat3 controls lysosomal-mediated cell death in vivo. Nat Cell Biol (2011) 13:303-9. doi:10.1038/ncb2171
36. Martinson HA, Jindal S, Durand-Rougely C, Borges VF, Schedin P. Wound healing-like immune program facilitates postpartum mammary gland involution and tumor progression. Int J Cancer (2015) 136:1803-13. doi:10.1002/ijc.29181
37. Vaught DB, Cook RS. Clearance of dying cells accelerates malignancy. Oncotarget (2015) 6:24590-1. doi:10.18632/oncotarget.5670
38. Lyons TR, Borges VF, Betts CB, Guo Q, Kapoor P, Martinson HA, et al. Cyclooxygenase-2-dependent lymphangiogenesis promotes nodal metastasis of postpartum breast cancer. J Clin Invest (2014) 124(9):3901-12. doi:10.1172/JCI73777
39. Gupta PB, Proia D, Cingoz O, Weremowicz J, Naber SP, Weinberg RA, et al. Systemic stromal effects of estrogen promote the growth of estrogen receptor-negative cancers. Cancer Res (2007) 67:2062-71. doi:10.1158/0008-5472.CAN-06-3895
40. Stanford JC, Young C, Hicks D, Owens P, Williams A, Vaught DB, et al. Efferocytosis produces a prometastatic landscape during postpartum mammary gland involution. J Clin Invest (2014) 124:4737-52. doi:10.1172/JCI76375
41. Swartz MA. Inflammatory lymphangiogenesis in postpartum breast tissue remodeling. J Clin Invest (2014) 124(9):1-4. doi:10.1172/JCI77765
42. Betterman K, Harvey N. The lymphatic vasculature: development and role in shaping immunity. Immunol Rev (2016) 27:276-92. doi:10.1111/imr.12413
43. Tammela T, Alitalo K. Lymphangiogenesis: molecular mechanisms and future promise. Cell (2010) 140:460-76. doi:10.1016/j.cell.2010.01.045
44. Butler MG, Isogai S, Weinstein BM. Lymphatic development. Birth Defects Res C Embryo Today (2009) 87:222-31. doi:10.1002/bdrc.20155
45. Schulte-Merker S, Sabine A, Petrova TV. Lymphatic vascular morphogenesis in development, physiology, and disease. J Cell Biol (2011) 193:607-18. doi:10.1083/jcb.201012094
46. Karpanen T, Makinen T. Regulation of lymphangiogenesis-from cell fate determination to vessel remodeling. Exp Cell Res (2006) 312:575-83. doi:10.1016/j.yexcr.2005.10.034
47. Karpanen T, Wirzenius M, Mäkinen T, Veikkola T, Haisma HJ, Achen MG, et al. Lymphangiogenic growth factor responsiveness is modulated by postnatal lymphatic vessel maturation. Am J Pathol (2006) 169:708-18. doi:10.2353/ajpath.2006.051200
48. Wigle JT, Harvey N, Detmar M, Lagutina I, Grosveld G, Gunn MD, et al. An essential role for Prox1 in the induction of the lymphatic endothelial cell phenotype. EMBO J (2002) 21:1505-13. doi:10.1093/emboj/21.7.1505
49. Pan Y, Wang WD, Yago T. Transcriptional regulation of podoplanin expression by Prox1 in lymphatic endothelial cells. Microvasc Res (2014) 94:96-102. doi:10.1016/j.mvr.2014.05.006
50. Norrmén C, Tammela T, Petrova TV, Alitalo K. Biological basis of therapeutic lymphangiogenesis. Circulation (2011) 123:1335-51. doi:10.1161/CIRCULATIONAHA.107.704098
51. Karkkainen MJ, Haiko P, Sainio K, Partanen J, Taipale J, Petrova TV, et al. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol (2004) 5:74-80. doi:10.1038/ni1013
52. Breiteneder-Geleff S, Soleiman A, Kowalski H, Horvat R, Amann G, Kriehuber E, et al. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol (1999) 154:385-94. doi:10.1016/S0002-9440(10)65285-6
53. Norrmén C, Ivanov KI, Cheng J, Zangger N, Delorenzi M, Jaquet M, et al. FOXC2 controls formation and maturation of lymphatic collecting vessels through cooperation with NFATc1. J Cell Biol (2009) 185:439-57. doi:10.1083/jcb.200901104
54. Petrova TV, Karpanen T, Norrmén C, Mellor R, Tamakoshi T, Finegold D, et al. Defective valves and abnormal mural cell recruitment underlie lymphatic vascular failure in lymphedema distichiasis. Nat Med (2004) 10:974-81. doi:10.1038/nm1094
55. Petrova TV, Mäkinen T, Mäkelä TP, Saarela J, Virtanen I, Ferrell RE, et al. Lymphatic endothelial reprogramming of vascular endothelial cells by the Prox-1 homeobox transcription factor. EMBO J (2002) 21:4593-9. doi:10.1093/emboj/cdf470
56. Johnson NC, Dillard ME, Baluk P, McDonald DM, Harvey NL, Frase SL, et al. Lymphatic endothelial cell identity is reversible and its maintenance requires Prox1 activity. Genes Dev (2008) 22:3282-91. doi:10.1101/gad.1727208
57. Shin JW. Prox1 promotes lineage-specific expression of fibroblast growth factor (FGF) receptor-3 in lymphatic endothelium: a role for FGF signaling in lymphangiogenesis. Mol Biol Cell (2005) 17:576-84. doi:10.1091/mbc.E05-04-0368
58. Podgrabinska S, Braun P, Velasco P, Kloos B, Pepper MS, Skobe M. Molecular characterization of lymphatic endothelial cells. Proc Natl Acad Sci U S A (2002) 99:16069-74. doi:10.1073/pnas.242401399
59. Klotz L, Norman S, Vieira JM, Masters M, Rohling M, Dubé KN, et al. Cardiac lymphatics are heterogeneous in origin and respond to injury. Nature (2015) 522:62-7. doi:10.1038/nature14483
60. Zheng W, Aspelund A, Alitalo K. Lymphangiogenic factors, mechanisms, and applications. J Clin Invest (2014) 124:878-87. doi:10.1172/JCI71603
61. Breier G. Lymphangiogenesis in regenerating tissue: is VEGF-C sufficient? Circ Res (2005) 96:1132-4. doi:10.1161/01.RES.0000170976.63688.ca
62. Achen MG, Jeltsch M, Kukk E, Mäkinen T, Vitali A, Wilks AF, et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci U S A (1998) 95:548-53. doi:10.1073/pnas.95.2.548
63. Cao Y, Linden P, Farnebo J, Cao R, Eriksson A, Kumar V, et al. Vascular endothelial growth factor C induces angiogenesis in vivo. Proc Natl Acad Sci U S A (1998) 95:14389-94. doi:10.1073/pnas.95.24.14389
64. Cao Y, Zhong W. Tumor-derived lymphangiogenic factors and lymphatic metastasis. Biomed Pharmacother (2007) 61:534-9. doi:10.1016/j.biopha.2007.08.009
65. Cao Z, Shang B, Zhang G, Miele L, Sarkar FH, Wang Z, et al. Tumor cell-mediated neovascularization and lymphangiogenesis contrive tumor progression and cancer metastasis. Biochim Biophys Acta (2013) 1836:273-86. doi:10.1016/j.bbcan.2013.08.001
66. Cao R, Eriksson A, Kubo H, Alitalo K, Cao Y, Thyberg J, et al. Comparative evaluation of FGF-2-, VEGF-A-, and VEGF-C-induced angiogenesis, lymphangiogenesis, vascular fenestrations, and permeability. Circ Res (2004) 94:664-70. doi:10.1161/01.RES.0000118600.91698.BB
67. Cao Y. Opinion: emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis. Nat Rev Cancer (2005) 5:735-43. doi:10.1038/nrc1693
68. Hall KL, Volk-Draper LD, Flister MJ, Ran S. New model of macrophage acquisition of the lymphatic endothelial phenotype. PLoS One (2012) 7:e31794. doi:10.1371/journal.pone.0031794
69. Ran S, Montgomery KE. Macrophage-mediated lymphangiogenesis: the emerging role of macrophages as lymphatic endothelial progenitors. Cancers (Basel) (2012) 4:618-57. doi:10.3390/cancers4030618
70. Björndahl MA, Cao R, Burton JB, Brakenhielm E, Religa P, Galter D, et al. Vascular endothelial growth factor-a promotes peritumoral lymphangiogenesis and lymphatic metastasis. Cancer Res (2005) 65:9261-8. doi:10.1158/0008-5472.CAN-04-2345
71. Gallego E, Vicioso L, Alvarez M, Hierro I, Pérez-Villa L, Blanes A, et al. Stromal expression of vascular endothelial growth factor C is relevant to predict sentinel lymph node status in melanomas. Virchows Arch (2011) 458:621-30. doi:10.1007/s00428-011-1044-7
72. Schoppmann SF, Fenzl A, Nagy K, Unger S, Bayer G, Geleff S, et al. VEGF-C expressing tumor-associated macrophages in lymph node positive breast cancer: impact on lymphangiogenesis and survival. Surgery (2006) 139:839-46. doi:10.1016/j.surg.2005.12.008
73. Schoppmann SF, Birner P, Stöckl J, Kalt R, Ullrich R, Caucig C, et al. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol (2002) 161:947-56. doi:10.1016/S0002-9440(10)64255-1
74. Skobe M, Hamberg LM, Hawighorst T, Schirner M, Wolf GL, Alitalo K, et al. Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. Am J Pathol (2001) 159:893-903. doi:10.1016/S0002-9440(10)61765-8
75. Zumsteg A, Baeriswyl V, Imaizumi N, Schwendener R, Rüegg C, Christofori G. Myeloid cells contribute to tumor lymphangiogenesis. PLoS One (2009) 4:e7067. doi:10.1371/journal.pone.0007067
76. Religa P, Cao R, Bjorndahl M, Zhou Z, Zhu Z, Cao Y. Presence of bone marrow-derived circulating progenitor endothelial cells in the newly formed lymphatic vessels. Blood (2005) 106:4184-90. doi:10.1182/blood-2005-01-0226
77. Jiang S, Bailey AS, Goldman DC, Swain JR, Wong MH, Streeter PR, et al. Hematopoietic stem cells contribute to lymphatic endothelium. PLoS One (2008) 3:e3812. doi:10.1371/journal.pone.0003812
78. Maruyama K, Ii M, Cursiefen C, Jackson DG, Keino H, Tomita M, et al. Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages. J Clin Invest (2005) 115:2363-72. doi:10.1172/JCI23874
79. Cursiefen C, Cao J, Chen L, Liu Y, Maruyama K, Jackson D, et al. Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci (2004) 45:2666-73. doi:10.1167/iovs.03-1380
80. Kerjaschki D. The crucial role of macrophages in lymphangiogenesis. J Clin Invest (2005) 115:2316-9. doi:10.1172/JCI26354
81. O'Brien J, Martinson H, Durand-Rougely C, Schedin P. Macrophages are crucial for epithelial cell death and adipocyte repopulation during mammary gland involution. Development (2012) 139:269-75. doi:10.1242/dev.071696
82. Alowami S, Troup S, Al-Haddad S, Kirkpatrick I, Watson PH. Mammographic density is related to stroma and stromal proteoglycan expression. Breast Cancer Res (2003) 5:R129-35. doi:10.1186/bcr622
83. Watson CJ, Oliver CH, Khaled WT. Cytokine signalling in mammary gland development. J Reprod Immunol (2011) 88(2):124-9. doi:10.1016/j.jri.2010.11.006
84. Walker NI, Bennett RE, Kerr JF. Cell death by apoptosis during involution of the lactating breast in mice and rats. Am J Anat (1989) 185:19-32. doi:10.1002/aja.1001850104
85. Richert MM, Schwertfeger KL, Ryder JW, Anderson SM. An atlas of mouse mammary gland development. J Mammary Gland Biol Neoplasia (2000) 5:227-41. doi:10.1023/A:1026499523505
86. Schwertfeger KL, Richert MM, Anderson SM. Mammary gland involution is delayed by activated Akt in transgenic mice. Mol Endocrinol (2001) 15:867-81. doi:10.1210/mend.15.6.0663
87. Monks J, Rosner D, Geske FJ, Lehman L, Hanson L, Neville MC, et al. Epithelial cells as phagocytes: apoptotic epithelial cells are engulfed by mammary alveolar epithelial cells and repress inflammatory mediator release. Cell Death Differ (2005) 12:107-14. doi:10.1038/sj.cdd.4401517
88. Rudolph MC, McManaman JL, Hunter L, Phang T, Neville MC. Functional development of the mammary gland: use of expression profiling and trajectory clustering to reveal changes in gene expression during pregnancy, lactation, and involution. J Mammary Gland Biol Neoplasia (2003) 8:287-307. doi:10.1023/B:JOMG.0000010030.73983.57
89. Monks J, Smith-Steinhart C, Kruk ER, Fadok VA, Henson PM. Epithelial cells remove apoptotic epithelial cells during post-lactation involution of the mouse mammary gland. Biol Reprod (2008) 78:586-94. doi:10.1095/biolreprod.107.065045
90. Pepper MS, Baetens D, Mandriota SJ, Di Sanza C, Oikemus S, Lane TF, et al. Regulation of VEGF and VEGF receptor expression in the rodent mammary gland during pregnancy, lactation, and involution. Dev Dyn (2000) 218:507-24. doi:10.1002/1097-0177(200007)218:3<507::AID-DVDY1012>3.0.CO;2-5
91. Betterman KL, Paquet-Fifield S, Asselin-Labat ML, Visvader JE, Butler LM, Stacker SA, et al. Remodeling of the lymphatic vasculature during mouse mammary gland morphogenesis is mediated via epithelial-derived lymphangiogenic stimuli. Am J Pathol (2012) 181:2225-38. doi:10.1016/j.ajpath.2012.08.035
92. Martinson H, Jindal S, Borges V, Schedin P. Immune cell influx during postpartum mammary gland involution reveals immunosuppression and tumor promotion. Cancer Res (2013):73.
93. Jindal S, Gao D, Bell P, Albrektsen G, Edgerton SM, Ambrosone CB, et al. Postpartum breast involution reveals regression of secretory lobules mediated by tissue-remodeling. Breast Cancer Res (2014) 16:R31. doi:10.1186/bcr3633
94. Kataru RP, Jung K, Jang C, Yang H, Schwendener RA, Baik JE, et al. Critical role of CD11b+ macrophages and VEGF in inflammatory lymphangiogenesis, antigen clearance, and inflammation resolution. Blood (2009) 113:5650-9. doi:10.1182/blood-2008-09-176776
95. Hamrah P, Chen L, Cursiefen C, Zhang Q, Joyce NC, Dana MR. Expression of vascular endothelial growth factor receptor-3 (VEGFR-3) on monocytic bone marrow-derived cells in the conjunctiva. Exp Eye Res (2004) 79:553-61. doi:10.1016/j.exer.2004.06.028
96. Xu H, Chen M, Reid DM, Forrester JV. LYVE-1-positive macrophages are present in normal murine eyes. Invest Ophthalmol Vis Sci (2007) 48:2162-71. doi:10.1167/iovs.06-0783
97. Qian B, Deng Y, Im JH, Muschel RJ, Zou Y, Li J, et al. A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. PLoS One (2009) 4:e6562. doi:10.1371/journal.pone.0006562
98. Barnes NL, Warnberg F, Farnie G, White D, Jiang W, Anderson E, et al. Cyclooxygenase-2 inhibition: effects on tumour growth, cell cycling and lymphangiogenesis in a xenograft model of breast cancer. Br J Cancer (2007) 96:575-82. doi:10.1038/sj.bjc.6603593
99. Timoshenko AV, Chakraborty C, Wagner GF, Lala PK. COX-2-mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer. Br J Cancer (2006) 94:1154-63. doi:10.1038/sj.bjc.6603067
100. Xin X, Majumder M, Girish GV, Mohindra V, Maruyama T, Lala PK. Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model. Lab Invest (2012) 92:1115-28. doi:10.1038/labinvest.2012.90
101. Liu H, Yang Y, Xiao J, Lv Y, Liu Y, Yang H, et al. Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via VEGF-C. Anat Rec (Hoboken) (2009) 292:1577-83. doi:10.1002/ar.20940
102. Bhattacharjee RN, Timoshenko AV, Cai J, Lala PK. Relationship between cyclooxygenase-2 and human epidermal growth factor receptor 2 in vascular endothelial growth factor C up-regulation and lymphangiogenesis in human breast cancer. Cancer Sci (2010) 101:2026-32. doi:10.1111/j.1349-7006.2010.01647.x
103. Ylöstalo JH, Bartosh TJ, Coble K, Prockop DJ. Human mesenchymal stem/stromal cells cultured as spheroids are self-activated to produce prostaglandin E2 that directs stimulated macrophages into an anti-inflammatory phenotype. Stem Cells (2012) 30:2283-96. doi:10.1002/stem.1191
104. Liu L, Ge D, Ma L, Mei J, Liu S, Zhang Q, et al. Interleukin-17 and prostaglandin E2 are involved in formation of an M2 macrophage-dominant microenvironment in lung cancer. J Thorac Oncol (2012) 7(7):1091-100. doi:10.1097/JTO.0b013e3182542752
105. Jain RK, Padera TP. Prevention and treatment of lymphatic metastasis by antilymphangiogenic therapy. J Natl Cancer Inst (2002) 94:785-7. doi:10.1093/jnci/94.11.785
106. Gudlaugsson E, Skaland I, Undersrud E, Janssen EA, Søiland H, Baak JP. D2-40/p63 defined lymph vessel invasion has additional prognostic value in highly proliferating operable node negative breast cancer patients. Mod Pathol (2011) 24:502-11. doi:10.1038/modpathol.2010.199
107. Schoppmann SF, Bayer G, Aumayr K, Taucher S, Geleff S, Rudas M, et al. Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann Surg (2004) 240:306-12. doi:10.1097/01.sla.0000133355.48672.22
108. Swartz MA, Skobe M. Lymphatic function, lymphangiogenesis, and cancer metastasis. Microsc Res Tech (2001) 55:92-9. doi:10.1002/jemt.1160
109. Achen MG, Stacker SA. Molecular control of lymphatic metastasis. Ann N Y Acad Sci (2008) 1131:225-34. doi:10.1196/annals.1413.020
110. Alitalo A, Detmar M. Interaction of tumor cells and lymphatic vessels in cancer progression. Oncogene (2012) 31:4499-508. doi:10.1038/onc.2011.602
111. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell (2002) 1:219-27. doi:10.1016/S1535-6108(02)00051-X
112. Baldwin ME, Stacker SA, Achen MG. Molecular control of lymphangiogenesis. Bioessays (2002) 24:1030-40. doi:10.1002/bies.10173
113. Jussila L, Alitalo K. Vascular growth factors and lymphangiogenesis. Physiol Rev (2002) 82:673-700. doi:10.1152/physrev.00005.2002
114. Karnezis T, Shayan R, Caesar C, Roufail S, Harris NC, Ardipradja K, et al. VEGF-D promotes tumor metastasis by regulating prostaglandins produced by the collecting lymphatic endothelium. Cancer Cell (2012) 21:181-95. doi:10.1016/j.ccr.2011.12.026
115. Karpanen T, Egeblad M, Karkkainen MJ, Kubo H, Ylä-Herttuala S, Jäättelä M, et al. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res (2001) 61:1786-90.
116. Liu H, Yang Y, Xiao J, Lv Y, Liu Y, Yang H, et al. COX-2-mediated regulation of VEGF-C in association with lymphangiogenesis and lymph node metastasis in lung cancer. Anat Rec (Hoboken) (2010) 293:1838-46. doi:10.1002/ar.21240
117. Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P, et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med (2001) 7:192-8. doi:10.1038/84643
118. Wang CA, Jedlicka P, Patrick AN, Micalizzi DS, Lemmer KC, Deitsch E, et al. SIX1 induces lymphangiogenesis and metastasis via upregulation of VEGF-C in mouse models of breast cancer. J Clin Invest (2012) 122:1895-906. doi:10.1172/JCI59858
119. Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R, et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med (2001) 7:186-91. doi:10.1038/84635
120. Katoh H, Hosono K, Ito Y, Suzuki T, Ogawa Y, Kubo H, et al. COX-2 and prostaglandin EP3/EP4 signaling regulate the tumor stromal proangiogenic microenvironment via CXCL12-CXCR4 chemokine systems. Am J Pathol (2010) 176:1469-83. doi:10.2353/ajpath.2010.090607
121. Su JL, Shih JY, Yen ML, Jeng YM, Chang CC, Hsieh CY, et al. Cyclooxygenase-2 induces EP1-and HER-2/Neu-dependent vascular endothelial growth factor-C up-regulation: a novel mechanism of lymphangiogenesis in lung adenocarcinoma. Cancer Res (2004) 64:554-64. doi:10.1158/0008-5472.CAN-03-1301
122. Mäkinen T, Veikkola T, Mustjoki S, Karpanen T, Catimel B, Nice EC, et al. Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J (2001) 20:4762-73. doi:10.1093/emboj/20.17.4762
123. Hoshida T, Isaka N, Hagendoorn J, di Tomaso E, Chen YL, Pytowski B, et al. Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: therapeutic implications. Cancer Res (2006) 66:8065-75. doi:10.1158/0008-5472.CAN-06-1392
124. Quagliata L, Klusmeier S, Cremers N, Pytowski B, Harvey A, Pettis RJ, et al. Inhibition of VEGFR-3 activation in tumor-draining lymph nodes suppresses the outgrowth of lymph node metastases in the MT-450 syngeneic rat breast cancer model. Clin Exp Metastasis (2014) 31:351-65. doi:10.1007/s10585-013-9633-2
125. Fornetti J, Jindal S, Middleton KA, Borges VF, Schedin P. Physiological COX-2 expression in breast epithelium associates with COX-2 levels in ductal carcinoma in situ and invasive breast cancer in young women. Am J Pathol (2014) 184:1219-29. doi:10.1016/j.ajpath.2013.12.026
126. Lewis C, Pollard J. Distinct role of macrophages in different tumor microenvironments. Cancer Res (2006) 66(2):605-12. doi:10.1158/0008-5472.CAN-05-4005
127. Kurahara H, Takao S, Maemura K, Mataki Y, Kuwahata T, Maeda K, et al. M2-polarized tumor-associated macrophage infiltration of regional lymph nodes is associated with nodal lymphangiogenesis and occult nodal involvement in pN0 pancreatic cancer. Pancreas (2013) 42:155-9. doi:10.1097/MPA.0b013e318254f2d1
128. Mantovani A, Romero P, Palucka AK, Marincola FM. Tumour immunity: effector response to tumour and role of the microenvironment. Lancet (2008) 371:771-83. doi:10.1016/S0140-6736(08)60241-X
129. Burton JB, Priceman SJ, Sung JL, Brakenhielm E, An DS, Pytowski B, et al. Suppression of prostate cancer nodal and systemic metastasis by blockade of the lymphangiogenic axis. Cancer Res (2008) 68:7828-37. doi:10.1158/0008-5472.CAN-08-1488
130. Pytowski B, Goldman J, Persaud K, Wu Y, Witte L, Hicklin DJ, et al. Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody. J Natl Cancer Inst (2005) 97:14-21. doi:10.1093/jnci/dji003
131. Roberts N, Kloos B, Cassella M, Podgrabinska S, Persaud K, Wu Y, et al. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. Cancer Res (2006) 66:2650-7. doi:10.1158/0008-5472.CAN-05-1843
132. Saif WM, Knost JA, Chiorean EG, Kambhampati SRP, Yu D, Pytowski B, et al. Phase I study of anti-VEGF receptor-3 (VEGFR-3) monoclonal antibody (Mab) LY3022856/IMC-3C5 (3C5). J Clin Oncol (2015) 33.
133. Mross K, Frost A, Scheulen ME, Krauss J, Strumberg D, Schultheiss B, et al. Phase I study of telatinib (BAY 57-9352): analysis of safety, pharmacokinetics, tumor efficacy, and biomarkers in patients with colorectal cancer. Vasc Cell (2011) 3:16. doi:10.1186/2045-824X-3-16
134. Marx J. Cancer. Encouraging results for second-generation antiangiogenesis drugs. Science (2005) 308:1248-9.